Company Overview

Update
Headquarters:
Cranbury, NJ
Funding:
$74.90M
Categories:
Biotechnology

Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.

Description

Update

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

Current Team (3)

Update

Board Members and Advisors (2)

Update

Acquisitions (1)

Update

Funding Rounds (4) - $74.90M

Update

Investors (3)

Update

Offices/Locations (1)

Update
  • Office

    1 Cedar Brook Drive

    Cranbury, NJ 08512

    USA

Images (1)

Update
  • 41ee4baea2f0bbdfb20442449ab94384